" class="no-js "lang="en-US"> ClariMed Launches Integrated Medical Device Services Partner
Thursday, April 11, 2024

ClariMed Launches Integrated Medical Device Services Partner

ClariMed has announced the launch of the first MedTech services partner to take an integrated, human-centric approach to medical product development. The Company also announced today the acquisition of San Jose-based UserWise, LLC, and the appointment of Kelley Kendle as Chief Executive Officer and Chair of the Board of Directors. The Company was formed in partnership with NaviMed Capital, a private investment firm focused exclusively on the healthcare industry.

ClariMed was formed to meet the MedTech industry’s growing need for an integrated partner focused on development and regulatory services. ClariMed embraces a human-centric approach to the MedTech product lifecycle, taking an integrated approach that differs from the current fragmented support ecosystem that sponsors face when bringing products to market and meeting regulatory requirements. With the increasing variety in users of medical products and growing regulatory requirements, MedTech innovators are struggling to find partners who can understand, coordinate, and meet the emerging requirements for human-centric product design and development.

With the appointment of Kelley Kendle as CEO and Board Chair, ClariMed is led by an executive with a wealth of experience in service-based businesses targeting medical device and pharmaceutical companies. She previously held executive positions as President and CEO of Synchrogenix (a subsidiary of Certara), as Chief Solutions Officer of Certara, a pharma-focused strategic regulatory services business, and as CEO of a European Medical Device CRO.

Kelley Kendle, CEO and Board Chair, commented, “Evolving FDA regulations and the EU Medical Device Regulation (MDR) are motivating medical product sponsors to continue their focus on risk mitigation. These sponsors need a strategic partner with a differentiated platform of services to guide them through development milestones while maintaining a constant awareness of evolving agency expectations. The ClariMed team will help our clients balance risk-benefit and get a usable product to the market faster. We will bring together experienced firms with differentiated services to provide a comprehensive offering and a multi-regional footprint. I look forward to building a team that will have such a significant impact on people’s lives.”

Shannon Clark, Founder & CEO at UserWise, commented, “We have attracted the best and brightest of next-generation human factors engineers and participant recruiters as we focus on building a world-class organization. We are experts in human factors for medical product development and leverage our individual experiences, which range from Fortune 500 medical product companies to leading start-ups, to empathize with in-house innovators to work seamlessly with their teams. This broader perspective that human factors is a small piece in a greater puzzle is the key to developing successful, usable medical products. We are excited to have the backing of ClariMed as we continue to pursue our common goals of maximizing the health, well-being, and safety of medical product patients and users.”

“We are excited to partner with UserWise, given the breadth of their expertise across medical products, including robotic surgery, home-use products, combination devices, and more,” said Brian Canann, ClariMed Board Member and Managing Director at NaviMed Capital.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more